240 related articles for article (PubMed ID: 15237854)
41. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F
Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
[TBL] [Abstract][Full Text] [Related]
42. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
[TBL] [Abstract][Full Text] [Related]
43. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
44. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
45. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M
Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874
[TBL] [Abstract][Full Text] [Related]
46. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M
Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265
[TBL] [Abstract][Full Text] [Related]
47. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
[TBL] [Abstract][Full Text] [Related]
48. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.
Schillevoort I; de Boer A; van der Weide J; Steijns LS; Roos RA; Jansen PA; Leufkens HG
Pharmacogenetics; 2002 Apr; 12(3):235-40. PubMed ID: 11927839
[TBL] [Abstract][Full Text] [Related]
49. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
Hayhurst GP; Harlow J; Chowdry J; Gross E; Hilton E; Lennard MS; Tucker GT; Ellis SW
Biochem J; 2001 Apr; 355(Pt 2):373-9. PubMed ID: 11284724
[TBL] [Abstract][Full Text] [Related]
50. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.
Zhou SF; Liu JP; Lai XS
Curr Med Chem; 2009; 16(21):2661-805. PubMed ID: 19601803
[TBL] [Abstract][Full Text] [Related]
51. Complexities of CYP2D6 gene analysis and interpretation.
Gaedigk A
Int Rev Psychiatry; 2013 Oct; 25(5):534-53. PubMed ID: 24151800
[TBL] [Abstract][Full Text] [Related]
52. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.
Ingelman-Sundberg M
Pharmacogenomics J; 2005; 5(1):6-13. PubMed ID: 15492763
[TBL] [Abstract][Full Text] [Related]
53. Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6.
Paine MJ; McLaughlin LA; Flanagan JU; Kemp CA; Sutcliffe MJ; Roberts GC; Wolf CR
J Biol Chem; 2003 Feb; 278(6):4021-7. PubMed ID: 12446689
[TBL] [Abstract][Full Text] [Related]
54. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
Dorado P; Peñas-Lledó EM; Llerena A
Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
[TBL] [Abstract][Full Text] [Related]
55. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A; Dorado P; Peñas-Lledó EM
Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
[TBL] [Abstract][Full Text] [Related]
56. Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.
Ford KA; Ryslik G; Sodhi J; Halladay J; Diaz D; Dambach D; Masuda M
Drug Metab Rev; 2015 Aug; 47(3):291-319. PubMed ID: 26024250
[TBL] [Abstract][Full Text] [Related]
57. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.
Wennerholm A; Johansson I; Massele AY; Lande M; Alm C; Aden-Abdi Y; Dahl ML; Ingelman-Sundberg M; Bertilsson L; Gustafsson LL
Pharmacogenetics; 1999 Dec; 9(6):707-14. PubMed ID: 10634133
[TBL] [Abstract][Full Text] [Related]
58. Quantitation of human cytochrome P450 2D6 protein with immunoblot and mass spectrometry analysis.
Yu AM; Qu J; Felmlee MA; Cao J; Jiang XL
Drug Metab Dispos; 2009 Jan; 37(1):170-7. PubMed ID: 18832475
[TBL] [Abstract][Full Text] [Related]
59. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
[TBL] [Abstract][Full Text] [Related]
60. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
